Navigation Links
ThromboGenics NV: Business Update
Date:5/14/2009

associated with current anti-coagulant therapy.

Patient recruitment for this trial is on track and it is anticipated that this study will conclude by the end of 2010.

TB-403 - Anti-cancer: Partnership with Roche progressing well - Phase Ib trial results expected by the end of 2009. In June 2008, ThromboGenics and its co-development partner BioInvent signed a strategic alliance deal with Roche for its novel anti-cancer agent, TB-403 (anti-PIGF). In January, 2009, ThromboGenics and BioInvent received their first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. ThromboGenics received EUR3 million of the overall EUR5 million success fee.

The clinical development of TB-403 is also progressing well with the results of a Phase Ib trial expected by the end of 2009. This Phase Ib trial is assessing TB-403's tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer.

Microplasmin for Vascular Disease - Initial partnering discussions. After the encouraging Phase II results presented last year, ThromboGenics is continuing to look for a partner to continue the further development of microplasmin for the treatment of stroke.

Pre-Clinical Highlights

Anti-VPAC - EUR3.2 million Grant Awarded to ThromboGenics for the continued development of Anti-VPAC for the treatment of thrombocytopenia - At the end of February 2009, ThromboGenics was awarded a grant of up to EUR3.2 million for the continued development of its Anti-VPAC1 (Vasoactive Intestinal Peptide/Pituitary Adenylyl Cyclase-Activating Peptide Receptor 1) antibody for the treatment of thrombocytopenia (low platelet count) after chemotherapy.

The grant was received from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) and is based on the successful completion
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
Breaking Biology Technology:Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... YORK, Oct. 25 American Oriental,Bioengineering, Inc. (NYSE: ... and nutraceutical products in China, today,announced that it plans ... 5, 2007 after the market close. The company ... at 4:30 pm,ET to discuss its fiscal third quarter ...
... (Nasdaq: KOSN ) today announced that it ... October 31, 2007, beginning at approximately,7:30 a.m. Eastern ... by Kosan,s Executives, Robert G. Johnson, Jr., M.D., ... Ph.D., Senior,Vice President, Drug Discovery and Preclinical Development, ...
... Codexis, Inc., a private,biotechnology company and leading ... of Codexis Laboratories Singapore,Pte. Ltd. (CLS). CLS is ... an expansion of the company,s research and development ... the company,s pharmaceuticals business in,both the innovator and ...
Cached Biology Technology:American Oriental Bioengineering Announces Reporting Date for Third Quarter 2007 Financial Results 2Kosan Biosciences to Host Research & Development Day on October 31, 2007 2Kosan Biosciences to Host Research & Development Day on October 31, 2007 3Codexis Opens Singapore Laboratory 2
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may ... as Acuity Market Intelligence reports that the long ... open. Acuity forecasts that intensifying demand for smart ... biometrics will drive a global market of 2.5 ... by 2020.   According to ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... the story. A young athlete who seems no different from ... under the baleful sun of a blistering summer day. ... a gene mutation that makes them particularly sensitive to heat, ... Medicine ( http://www.bcm.edu ) may have identified a molecule ...
... living cells do is carried out by "molecular machines" ... some biological function. How the minute steps of evolution produced ... target for creationists. In a study published early online ... of scientists from the University of Chicago and the University ...
... new University of Florida study shows genomes of a ... phenomenon that may have far-reaching evolutionary consequences. Published ... National Academy of Sciences , the study is the ... a recently formed plant species following whole genome doubling, ...
Cached Biology News:Exercise in a pill may protect against extreme heat sensitivity 2Evolution of complexity recreated using 'molecular time travel' 2Evolution of complexity recreated using 'molecular time travel' 3Evolution of complexity recreated using 'molecular time travel' 4UF research on newly formed plants could lead to improved crop fertility 2UF research on newly formed plants could lead to improved crop fertility 3
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Biology Products: